UA118286C2 - Білок агоніст рецептора trail - Google Patents

Білок агоніст рецептора trail

Info

Publication number
UA118286C2
UA118286C2 UAA201611802A UAA201611802A UA118286C2 UA 118286 C2 UA118286 C2 UA 118286C2 UA A201611802 A UAA201611802 A UA A201611802A UA A201611802 A UAA201611802 A UA A201611802A UA 118286 C2 UA118286 C2 UA 118286C2
Authority
UA
Ukraine
Prior art keywords
receptor agonist
agonist proteins
trail
chain trail
trail receptor
Prior art date
Application number
UAA201611802A
Other languages
English (en)
Inventor
Олівер Гіл
Кристіан Ґіферс
Майнольф Тіман
Фриц Ґ. Б'юканан
Дарен К. Філіпс
Сьюзан Е. Леп
Original Assignee
Еббві Інк.
Апоґенікс Аґ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Еббві Інк., Апоґенікс Аґ filed Critical Еббві Інк.
Publication of UA118286C2 publication Critical patent/UA118286C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)

Abstract

Винахід належить до специфічного білка-агоніста рецептора TRAIL, нуклеїнової кислоти, кодуючої його, і способу лікування пацієнта, що має TRAIL-асоційоване захворювання або розлад. Білок-агоніст рецептора TRAIL включає три розчинних домени TRAIL і Fc-фрагмент. Білок-агоніст рецептора TRAIL є по суті неагрегуючим і придатним для терапевтичного, діагностичного і/або дослідницького застосування.
UAA201611802A 2014-04-23 2015-04-23 Білок агоніст рецептора trail UA118286C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23
PCT/US2015/027270 WO2015164588A1 (en) 2014-04-23 2015-04-23 Single-chain trail-receptor agonist proteins

Publications (1)

Publication Number Publication Date
UA118286C2 true UA118286C2 (uk) 2018-12-26

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201611802A UA118286C2 (uk) 2014-04-23 2015-04-23 Білок агоніст рецептора trail

Country Status (37)

Country Link
US (4) US9908927B2 (uk)
EP (2) EP3134430B1 (uk)
JP (2) JP6523331B2 (uk)
KR (2) KR102079919B1 (uk)
CN (2) CN106459221B (uk)
AR (1) AR100168A1 (uk)
AU (3) AU2015249649B2 (uk)
BR (1) BR112016024515B1 (uk)
CA (2) CA2946402C (uk)
CL (1) CL2016002683A1 (uk)
CR (1) CR20160516A (uk)
CY (1) CY1120281T1 (uk)
DK (1) DK3134430T3 (uk)
DO (1) DOP2016000284A (uk)
EC (1) ECSP16089579A (uk)
ES (1) ES2672368T3 (uk)
HR (1) HRP20180950T1 (uk)
HU (1) HUE038914T2 (uk)
IL (2) IL248244B (uk)
LT (1) LT3134430T (uk)
MA (2) MA45069A (uk)
MX (2) MX2016013858A (uk)
MY (1) MY181986A (uk)
NO (1) NO2776305T3 (uk)
PE (1) PE20170299A1 (uk)
PH (1) PH12016502079B1 (uk)
PL (1) PL3134430T3 (uk)
PT (1) PT3134430T (uk)
RS (1) RS57153B1 (uk)
RU (1) RU2699285C2 (uk)
SG (3) SG10202111785VA (uk)
SI (1) SI3134430T1 (uk)
TR (1) TR201806912T4 (uk)
TW (2) TWI683825B (uk)
UA (1) UA118286C2 (uk)
UY (1) UY36095A (uk)
WO (1) WO2015164588A1 (uk)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107709355B (zh) * 2015-05-04 2021-09-14 阿珀吉尼科斯股份公司 单链cd40受体激动剂蛋白
CN108430492B (zh) 2015-10-23 2022-05-03 阿珀吉科吉尼科斯股份公司 单链cd27受体激动剂蛋白
WO2017068185A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain gitr-receptor agonist proteins
CN108699129A (zh) 2015-10-23 2018-10-23 阿珀吉科吉尼科斯股份公司 单链light受体激动剂蛋白
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
US10821160B2 (en) 2016-03-01 2020-11-03 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability
US20190077870A1 (en) * 2016-03-16 2019-03-14 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR20190017804A (ko) * 2016-06-13 2019-02-20 메리맥 파마슈티컬즈, 인크. 환자를 선별하고 trail-기반 치료제 또는 사멸 수용체 효능제로 치료하는 방법
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
AU2018313253A1 (en) * 2017-08-11 2020-02-27 The Board Of Trustees Of The University Of Illinois Truncated guinea pig L-asparaginase variants and methods of use
WO2019178433A1 (en) * 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
TW202003553A (zh) * 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療癌症之abbv-621與抗癌劑之組合
WO2021229103A2 (en) 2020-05-15 2021-11-18 Apogenix Ag Multi-specific immune modulators
EP4346885A1 (en) 2021-05-28 2024-04-10 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7645700A (en) 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
JP2004528014A (ja) 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１融合タンパク質
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003091447A2 (en) 2002-04-26 2003-11-06 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
JP2008535909A (ja) * 2005-04-15 2008-09-04 ラパポート ファミリー インスティテュート フォー リサーチ イン ザ メディカル サイエンシーズ Ｍｃｐ−１／ｃｃｒ２関連疾患を治療するための分子およびその使用方法
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
EP2484691B1 (en) 2007-07-10 2016-01-13 Apogenix GmbH TNF superfamily collectin fusion proteins
AR072001A1 (es) 2008-06-03 2010-07-28 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
EP3103875A1 (en) 2008-07-21 2016-12-14 Apogenix AG Tnfsf single chain molecules
JP2012502994A (ja) 2008-09-22 2012-02-02 アムジエン・インコーポレーテツド 治療方法
AU2009303304A1 (en) * 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind TRAIL-RI and TRAIL-R2
ES2593049T3 (es) 2009-01-09 2016-12-05 Apogenix Ag Proteínas de fusión que forman trímeros
MX2011007833A (es) * 2009-01-23 2011-10-06 Biogen Idec Inc Polipeptidos fc estabilizados con funcion efectora reducida y metodos de uso.
CA2785139A1 (en) 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
US20130079280A1 (en) * 2010-04-13 2013-03-28 Medlmmune, Llc Fibronectin type iii domain-based multimeric scaffolds
WO2013092998A1 (en) * 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
DK2875045T3 (en) * 2012-07-18 2018-07-02 Apogenix Ag COMPOSITION comprising a mixture of CD95-FC ISOFORMs

Also Published As

Publication number Publication date
RU2699285C2 (ru) 2019-09-04
TW202024123A (zh) 2020-07-01
AU2020202247A1 (en) 2020-04-23
MX2016013858A (es) 2017-08-02
TWI683825B (zh) 2020-02-01
US20150337027A1 (en) 2015-11-26
JP2019162114A (ja) 2019-09-26
RU2016145608A3 (uk) 2018-12-26
ES2672368T3 (es) 2018-06-14
CA2946402C (en) 2023-02-28
MA39770A (fr) 2015-10-29
CN111718424A (zh) 2020-09-29
ECSP16089579A (es) 2018-05-31
KR20170012257A (ko) 2017-02-02
BR112016024515A2 (pt) 2017-10-10
HRP20180950T1 (hr) 2018-08-10
EP3134430B1 (en) 2018-03-21
AR100168A1 (es) 2016-09-14
WO2015164588A1 (en) 2015-10-29
SG10202111785VA (en) 2021-12-30
BR112016024515B1 (pt) 2020-03-31
AU2015249649B2 (en) 2018-10-04
CR20160516A (es) 2017-05-10
CN106459221B (zh) 2020-09-01
JP2017513503A (ja) 2017-06-01
MX2019013587A (es) 2020-01-13
CA2946402A1 (en) 2015-10-29
EP3134430A1 (en) 2017-03-01
US9908927B2 (en) 2018-03-06
US20210040178A1 (en) 2021-02-11
IL248244B (en) 2020-03-31
SG11201608767XA (en) 2016-11-29
AU2018271369A1 (en) 2018-12-20
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
SI3134430T1 (en) 2018-05-31
CL2016002683A1 (es) 2017-07-07
RU2016145608A (ru) 2018-05-28
MY181986A (en) 2021-01-18
PH12016502079A1 (en) 2016-12-19
DOP2016000284A (es) 2017-02-15
PH12016502079B1 (en) 2016-12-19
US20180222962A1 (en) 2018-08-09
PL3134430T3 (pl) 2018-08-31
AU2015249649A1 (en) 2016-11-10
NO2776305T3 (uk) 2018-01-27
JP6523331B2 (ja) 2019-05-29
AU2018271369B2 (en) 2020-01-02
US20240174731A1 (en) 2024-05-30
CY1120281T1 (el) 2019-07-10
NZ725476A (en) 2023-09-29
TWI747178B (zh) 2021-11-21
EP3366699A1 (en) 2018-08-29
JP6714751B2 (ja) 2020-06-24
DK3134430T3 (en) 2018-05-22
PT3134430T (pt) 2018-04-20
IL248244A0 (en) 2016-11-30
TW201620928A (zh) 2016-06-16
MA45069A (fr) 2019-04-03
SG10201806465TA (en) 2018-08-30
IL272612A (en) 2020-03-31
KR20190135546A (ko) 2019-12-06
KR102079919B1 (ko) 2020-02-24
HUE038914T2 (hu) 2018-12-28
LT3134430T (lt) 2018-05-10
PE20170299A1 (es) 2017-05-06
RS57153B1 (sr) 2018-07-31
UY36095A (es) 2015-10-30
TR201806912T4 (tr) 2018-06-21

Similar Documents

Publication Publication Date Title
MX2019013587A (es) Proteinas agonistas del receptor del ligando que induce la apoptosis relacionada con el factor de necrosis de tumor de cadena individual.
MX2017014140A (es) Proteinas agonistas receptoras cd40 de cadena simple.
IL278014A (en) Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
IL251194A0 (en) Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
HK1254755A1 (zh) 抗-肌肉生長抑制因子抗體、包含變體fc區的多肽及使用方法
PH12016501644A1 (en) Binding proteins and methods of use thereof
MX2018001787A (es) Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas.
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
UA117045C2 (uk) Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
IL254242A0 (en) Dual signaling fusion proteins and methods of using them to treat diseases
MX2016012219A (es) Agonistas de receptor fgf21 y usos del mismo.
MX2017011991A (es) Terapia virica con una combinacion de anticuerpos.
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
EP3227681A4 (en) Anti-acetaminophen antibodies and acetaminophen protein adducts
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
EP3925979A3 (en) Fgfr-tacc fusion proteins and methods thereof
NZ761611A (en) Single-chain trail-receptor agonist proteins
SG11201703624PA (en) Compounds for the diagnosis or treatment of disorders associated with protein or peptide oligomers
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.
EA202092450A2 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей